RESUMO
Objective: The SLE Responder Index (SRI) is a composite endpoint used in SLE trials. This investigation examined the clinical trial elements that drive response measured by the SRI. Methods: Analyses are based on data from two phase 3 trials (n = 2262) that evaluated the impact of an anti-B-cell activating factor antibody on disease activity using SRI-5 as the primary endpoint (ClinicalTrials.gov NCT01196091 and NCT01205438). Results: The SRI-5 response rate at week 52 for all patients was 32.8%. Non-response due to a lack of SLEDAI improvement, concomitant medication non-compliance or dropout was 31, 16.5 and 19.1%, respectively. Non-response due to deterioration in BILAG or Physician's Global Assessment after SLEDAI improvement, concomitant medication compliance and trial completion was 0.5%. Disease activity in three SLEDAI organ systems was highly prevalent at baseline: mucocutaneous, 90.6%; musculoskeletal, 82.9%; and immunologic, 71.6%. Disease activity in each of the other organ systems was <11% of patients. Four clinical manifestations were highly prevalent at baseline: arthritis, 82.6%; rash, 69.2%; alopecia, 58.2%; and mucosal ulcer, 32.5%. The combined prevalence of renal, vascular and CNS disease at baseline was 17.6%; these patients had high SRI-5 response rates. Adjustments to corticosteroids were allowed during the first 24 weeks. Increases in corticosteroids above 2.5 mg/day were observed in 16.2% of placebo patients over the first 24 weeks after randomization. Conclusion: The primary drivers of SRI-5 response were SLEDAI improvement, concomitant medication adherence and trial completion. Arthritis, rash, alopecia and mucosal ulcer were the most prevalent clinical manifestations at baseline. Corticosteroid increases and rare, highly weighted disease manifestations in SLEDAI can confound the SRI signal.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Corticosteroides/uso terapêutico , Fator Ativador de Células B/antagonistas & inibidores , Ensaios Clínicos como Assunto , Ensaios Clínicos Fase III como Assunto , Quimioterapia Combinada , Humanos , Lúpus Eritematoso Sistêmico/fisiopatologia , Adesão à Medicação , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
Nursing staff's knowledge of residents' lives in long-term care is critical to the provision of quality care, the formation of strong relationships between staff and residents, and the promotion of psychosocial well-being for residents. This study examines the degree to which nursing staff in assisted living facilities and nursing homes know residents in terms of their lives and occupations, family members, tastes and interests, and medical conditions. Quantitative surveys were administered to nursing staff-resident dyads (N = 199) as part of a larger study on quality of life in long-term care. Results indicated that while nursing staff generally knew residents fairly well, a significant percentage of nursing staff reported knowing nothing at all in each of the categorical areas of residents' lives. Implications center on eliminating barriers to knowledge attainment and implementing educational interventions that may augment nursing staff's knowledge of residents.